UNASSIGNED: This study investigates whether the use of levetiracetam and/or lacosamide impacts survival rates. The secondary aim was to evaluate the efficacy of both ASMs in controlling seizures.
UNASSIGNED: In this observational retrospective single-cohort study, patients underwent chemoradiation protocol after GBM surgery. They were grouped as follows: (1) use of levetiracetam, (2) use of lacosamide, (3) simultaneous use of levetiracetam and lacosamide, (4) no ASM usage. Survival curves were plotted using the Kaplan-Meier method coupled with a log-rank test for difference assesments. To evaluate the pharmacological efficacy of post-operative seizure control, a negative binomial regression was conducted.
UNASSIGNED: The study included 272 patients, 174 of which underwent adjuvant chemoradiation treatment. Patients without ASM therapy had a non-significant longer median OS (compared to the other groups (log-rank = 0.37). The IRR of seizure relapse was 2.57 (p = 0.007) times higher in lacosamide users, and MGMT promoter methylation demonstrated a protective effect against postoperative seizure onset (p = 0.05), regardless of the aforementioned confounding factors.
UNASSIGNED: In patients diagnosed with GBM IDH-WT undergoing chemoradiation therapy, the use of levetiracetam or lacosamide for controlling BTRE does not seem to modify survival. Lacosamide users exhibited a higher IRR of postoperative seizures compared to levetiracetam users, and MGMT promoter methylation appears to be a protective factor.
■本研究调查了使用左乙拉西坦和/或拉科沙胺是否会影响生存率。次要目的是评估两种ASM控制癫痫发作的功效。
■在这项观察性回顾性单队列研究中,患者在GBM手术后接受放化疗方案。它们被分组如下:(1)使用左乙拉西坦,(2)使用拉科沙胺,(3)同时使用左乙拉西坦和拉科沙胺,(4)没有ASM使用。使用Kaplan-Meier方法绘制生存曲线,并进行对数秩检验以进行差异评估。评估术后癫痫发作控制的药理作用,进行负二项回归。
■该研究包括272名患者,其中174例接受了辅助放化疗治疗。未接受ASM治疗的患者的中位OS无明显延长(与其他组相比(log-rank=0.37)。拉科沙胺使用者癫痫发作复发的IRR为2.57(p=0.007)倍,MGMT启动子甲基化显示了对术后癫痫发作的保护作用(p=0.05),不考虑上述混杂因素。
■在接受放化疗治疗的GBMIDH-WT患者中,使用左乙拉西坦或拉科沙胺控制BTRE似乎不会改变生存率.与左乙拉西坦使用者相比,Lacosamide使用者表现出更高的术后癫痫发作IRR,MGMT启动子甲基化似乎是一种保护因素。